Working... Menu

Pilot Study of the TearCare System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03006978
Recruitment Status : Active, not recruiting
First Posted : December 30, 2016
Last Update Posted : August 8, 2017
Information provided by (Responsible Party):
Sight Sciences, Inc.

Brief Summary:
The purpose of this study is to evaluate the clinical utility, safety, and effectiveness of the TearCare™ System compared to standardized warm compress therapy for the application of controlled, localized heat therapy in adult patients with dry eye syndrome.

Condition or disease Intervention/treatment Phase
Dry Eye Device: TearCare Device: Warm Compress Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of the TearCare System
Study Start Date : December 2016
Actual Primary Completion Date : March 2017
Estimated Study Completion Date : February 2018

Arm Intervention/treatment
Experimental: TearCare
Subjects will receive a 12-minute treatment session with the TearCare System followed by manual expression of the meibomian glands.
Device: TearCare
Active Comparator: Warm Compress
Subjects will apply a warm compress to the eyelids for 5 minutes daily for 4 weeks.
Device: Warm Compress

Primary Outcome Measures :
  1. Tear Breakup Time [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Meibomian Gland Assessment [ Time Frame: Day 1, Week 2, Week 4, 3 Month, 6 Month ]
  2. Dry Eye Symptoms and Quality of Life [ Time Frame: Week 2, Week 4, 3 Month, 6 Month ]
  3. Change in Medication Use [ Time Frame: Day 1, Week 2, Week 4, 3 Month, 6 Month ]
  4. Adverse Events [ Time Frame: Day 0, Day 1, Week 2, Week 4, 3 Month, 6 Month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Dry eye symptoms within 30 months of the screening exam with a SPEED score >=6
  • Schirmer 1 value of <010 mm in at least one eye or a Tear Breakup time <10 seconds in at least one eye

Exclusion Criteria:

  • Any active ocular or peri-ocular infection or inflammation
  • Recurrent eye inflammation within the past 3 months
  • Ocular surgery, oculoplastic surgery, ocular injury, Ocular Herpes Simplex, or Herpes Zoster
  • Ocular surface abnormalities that may affect tear film distribution or treatment
  • Abnormal eyelid function in either eye
  • Diminished or abnormal facial, periocular, ocular or corneal sensation
  • Ocular surface abnormalities such as corneal epithelial defects, ulcers, corneal dystrophies
  • Systemic diseases resulting in dry eye (e.g. Sjogren's syndrome)
  • Allergies to silicone tissue adhesives
  • An absence or fibrosis of the Meibomian glands (e.g. ectodermal dysplasia).
  • Unwillingness to abstain for the duration of the study from systemic medication known to cause ocular dryness (e.g. Accutane, antihistamines, etc.)
  • Anyone who requires chronic use (i.e. for any portion of the study) of topical ophthalmic antibiotics, steroids, non-steroidal anti-inflammatory medications or who has been on any of these medications within the past 30 days.
  • Unwillingness to washout and remain off certain dry eye medications for the duration of the study.
  • Participation in another ophthalmic clinical trial within the past 30 days
  • Co-existing conditions that could interfere with the assessment of safety or efficacy of treatment (e.g. macular disease, pregnancy, nursing, etc.)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03006978

Layout table for location information
United States, Illinois
Central Eye Care, Ltd.
Arlington Heights, Illinois, United States, 60005
Sponsors and Collaborators
Sight Sciences, Inc.

Layout table for additonal information
Responsible Party: Sight Sciences, Inc. Identifier: NCT03006978     History of Changes
Other Study ID Numbers: 05429
First Posted: December 30, 2016    Key Record Dates
Last Update Posted: August 8, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No